Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Biomaterials. 2013 Feb 27;34(15):3828–3836. doi: 10.1016/j.biomaterials.2013.02.031

Fig. 4.

Fig. 4

Effect of treatment on leukocyte subset changes. C57BL/6J mice (n=6 per group) bearing MC38 flank tumors received i.t. injections of DPBS, chitosan alone, IL-12(1μg) alone or chitosan/IL-12(1μg) on days 7 and 14. On day 17, A, tumors, and B, TDLNs were harvested and viable leukocytes stained with fluorescence-labeled antibodies for subsequent flow cytometry analysis. Data are presented as mean ± standard deviation. *P<0.05 vs. DPBS; ** P<0.05 vs. chitosan; *** P<0.05 vs. IL-12.